- Conditions
- Alcohol Use Disorder (AUD), HIV
- Interventions
- semaglutide
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Decatur, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 80,945
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ulcerative Colitis
- Interventions
- RO7837195, RO7837195 Matched Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 9
- States / cities
- Lancaster, California • San Diego, California • Colorado Springs, Colorado + 6 more
- Conditions
- Basal-Like Breast Carcinoma, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Breast Carcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Hereditary Breast and Ovarian Cancer Syndrome, Ovarian Carcinoma, Pancreatic Carcinoma, Progesterone Receptor Negative, Prostate Carcinoma, Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Solid Neoplasm, Triple-Negative Breast Carcinoma
- Interventions
- Laboratory Biomarker Analysis, Pharmacological Study, Veliparib
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 19 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 7
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 4 more
- Conditions
- Urolithiasis
- Interventions
- Not listed
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 0 Years to 18 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation
- Interventions
- Not listed
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- Not listed
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Hypercholesterolemia, Hypertension
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Cancer Metastatic
- Interventions
- Avasopasem
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Supraventricular Tachycardia
- Interventions
- New Ablation Technique, Standard Ablation Technique
- Procedure
- Lead sponsor
- Jeffrey Moak
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 5
- States / cities
- Washington D.C., District of Columbia • Hollywood, Florida • Iowa City, Iowa + 2 more
- Conditions
- Articular Cartilage, Cartilage Diseases
- Interventions
- Carticel (autologous cultured chondrocyte) implantation
- Biological
- Lead sponsor
- Vericel Corporation
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2009
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Medication Adherence, Satisfaction, Personal
- Interventions
- TAD
- Device
- Lead sponsor
- Intent Solutions, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Gainesville, Florida • Lake City, Florida • Palatka, Florida
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown Primary, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Metastatic Paranasal Sinus Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Paranasal Sinus Squamous Cell Carcinoma, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Lovastatin, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography
- Procedure · Drug · Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin's Disease
- Interventions
- SB-743921
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 6
- States / cities
- Hackensack, New Jersey • New York, New York • Chapel Hill, North Carolina + 1 more
- Conditions
- Sarcoid Uveitis
- Interventions
- H.P. Acthar gel
- Drug
- Lead sponsor
- John Huang, MD
- Other
- Eligibility
- Not listed
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Hamden, Connecticut
- Conditions
- Ocular Hypertension, Primary Open-Angle Glaucoma
- Interventions
- AGN-210961 Formulation 1, AGN-210961 Formulation 2, AGN-210961 Formulation 3, AGN-210961 Formulation 4, AGN-210961 Formulation 5, AGN-210961 Formulation 6, AGN-210961 Formulation 7, bimatoprost ophthalmic solution 0.03%
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Muscle Invasive Bladder Cancer
- Interventions
- Durvalumab, Tremelimumab, Enfortumab Vedotin, Radical Cystectomy
- Drug · Procedure
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 712 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 31
- States / cities
- Orange, California • Santa Monica, California • New Haven, Connecticut + 28 more
- Conditions
- Hematological Malignancy, Neutropenia
- Interventions
- Not listed
- Lead sponsor
- Aaron Cumpston, PharmD, BCOP
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Locally Advanced or Metastatic Breast Cancer
- Interventions
- Phesgo, Giredestrant, Docetaxel, Paclitaxel, LHRH Agonist, Optional Endocrine Therapy of Investigator's Choice
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 922 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 7 more
- Conditions
- Residual Neuromuscular Blockade
- Interventions
- Neostigmine, Sugammadex
- Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
- Conditions
- Colon Adenocarcinoma, High-Frequency Microsatellite Instability, Metastatic Malignant Solid Neoplasm, Rectal Adenocarcinoma, Refractory Colorectal Carcinoma, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8
- Interventions
- Anti-PD-L1/TGFbetaRII Fusion Protein M7824
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Colorectal Neoplasms, Metastases, Neoplasm
- Interventions
- Erbitux (Cetuximab)
- Biological
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Saint Charles, Missouri
- Conditions
- Craniocerebral Trauma, Stroke, Intracranial Hemorrhages
- Interventions
- Early cranioplasty, Standard-of-care cranioplasty
- Procedure
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Anal Cancer
- Interventions
- fluorouracil, mitomycin C, Intensity-modulated radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 169
- States / cities
- Tucson, Arizona • Auburn, California • Burbank, California + 128 more
- Conditions
- Snake Bite
- Interventions
- Crotalinae (pit viper) equine immune F(ab)2, Crotalidae Polyvalent Immune Fab, ovine
- Biological
- Lead sponsor
- Instituto Bioclon S.A. de C.V.
- Industry
- Eligibility
- 2 Years to 80 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Loma Linda, California + 10 more
- Conditions
- Inflammatory Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Interventions
- doxorubicin hydrochloride, cyclophosphamide, tipifarnib, filgrastim, therapeutic conventional surgery, laboratory biomarker analysis
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- The Bronx, New York